Tingley Whittemore 4

What Happened
Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics (TNYA), reported three sales on Feb 17, 2026 totaling 5,160 shares for combined proceeds of approximately $3,318. The reported transactions were: 1,642 shares for $1,056; a second 1,642-share sale for $1,056; and 1,876 shares for $1,206. All transactions are reported as sales (S) and were done in open market or private sale transactions.

Key Details

• Transaction date: February 17, 2026. Report filed the same day (no late filing indicated).
• Reported prices: filing shows $0.64 per share used for each line; footnote F2 states the actual sale prices ranged from $0.6075 to $0.671 and the $0.64 reflects the weighted average. Reporting person will provide detailed price breakdown on request.
• Reason for sale: Footnotes F1, F4 and F6 state the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). (Tax-withholding sales are routine and not necessarily a sentiment signal.)
• Unvested/other holdings noted in filing: footnotes reference unissued RSUs and other shares — e.g., 130,213 RSUs and 5,102 ESPP shares (F3); 125,838 RSUs (F5); 120,838 RSUs (F7) — indicating the reporting person continues to have substantial future equity subject to vesting.
• Transaction type codes: S = Sale; F (as used in footnotes) = tax withholding.

Context
These sales were executed to satisfy tax-withholding from RSU vesting, a common administrative transaction. Sales to cover taxes are generally considered routine and do not necessarily reflect the insider’s view of the company’s prospects. For retail investors, purchases or large discretionary sales tend to be more informative than tax-withholding disposals.